HEPATITIS C VIRUS PROTEASE

Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.

Description: HEPATITIS C VIRUS PROTEASE Cross-Reference to Related Applications This application is a continuation-in-part application of U.S. Serial No. 07/505,433, filed on 4 April 1990. Technical Field This invention relates to the molecular biology and virology of the hepatitis C virus (HCV). More specifically, this invention relates to a novel protease produced by HCV, methods of expression, recombinant protease, prote¬ ase mutants, and inhibitors of HCV protease. Background of the Invention Non-A, Non-B hepatitis (NANBH) is a transmissible disease (or family of diseases) that is believed to be virally induced, and is distinguishable from other forms of virus-associated liver disease, such as those caused by hep¬ atitis A virus (HAV), hepatitis B virus (HBV), delta hepatitis virus (HDV), cyto- megalovirus (CMV) or Epstein-Barr virus (EBV). Epidemiologic evidence sug¬ gests that there may be three types of NANBH: the water-borne epidemic type; the blood or needle associated type; and the sporadically occurring (community acquired) type. However, the number of causative agents i -mknown. Recently, however, a new viral species, hepatitis C virus (HCV) has b ≤n identified as the primary (if not only) cause of blood-associated NANBH (BB-NANBH). See for example, PCT WO89/046699; U.S. Patent Application Serial No. 7/456,637, filed 21 December 1989; and U.S. Patent Application Serial No. 7/456,637, filed 21 December 1989, incorporated herein by reference. Hepatitis C appears to be the major form of transfusion-associated hepatitis in a number of countries, including the United States and Japan. There is also evidence implicating HCV in induc¬ tion of hepatocellular carcinoma. Thus, a need exists for an effective method for treating HCV infection: currently, there is none. Many viruses, including adenoviruses, baculoviruses, comoviruses, picornaviruses, retroviruses, and togaviruses, rely on specific, virally-encoded pro- teases for processing polypeptides from their initial translated form into mature, active proteins. In the case of picornaviruses, all of the viral proteins are believed to arise from cleavage of a single polyprotein (B.D. Korant, CRC Crit Rev Biotech (1988) & 149-57). S. Pichuantes et al, in "Viral Proteinases As Targets For Chemother- apy" (Cold Spring Harbor Laboratory Press, 1989) pp. 215-22, disclosed expression of a viral protease found in HIV-1. The HIV protease was obtained in the form of a fusion protein, by fusing DNA encoding an HIV protease precursor to DNA encoding human superoxide dismutase (hSOD), and expressing the product in E. coli. Transformed cells expressed products of 36 and 10 kDa (corresponding to the hSOD-protease fusion protein and the protease alone), suggesting that the protease was expressed in a form capable of autocatalytic proteolysis. TJ. McQuade et al, Science (1990) 242:454-56 disclosed preparation of a peptide mimic capable of specifically inhibiting the HIV-1 protease. In HIV, the protease is believed responsible for cleavage of the initial p55 gag precursor transcript into the core structural proteins (pl7, p24, p8, and p7). Adding 1 μM inhibitor to HIV-infected peripheral blood lymphocytes in culture reduced the concentration of processed HIV p24 by about 70%. Viral maturation and levels of infectious virus were reduced by the protease inhibitor. Disclosure of the Invention We have now invented recombinant HCV protease, HCV protease fusion proteins, truncated and altered HCV proteases, cloning and expression vec¬ tors therefore, and methods for identifying antiviral agents effective for treating HCV. Brief Description of the Drawings Figure 1 shows the sequence of HCV protease. Figure 2 shows the polynucleotide sequence and deduced amino acid sequence of the clone C20c. Figure 3 shows the polynucleotide sequence and deduced amino acid sequence of the clone C26d. Figure 4 shows the polynucleotide sequence and deduced amino acid sequence of the clone C8h. Figure 5 shows the polynucleotide sequence and deduced amino acid sequence of the clone C7f. Figure 6 shows the polynucleotide sequence and deduced amino acid sequence of the clone C31. Figure 7 shows the polynucleotide sequence and deduced amino acid sequence of the clone C35. Figure 8 shows the polynucleotide sequence and deduced amino acid sequence of the clone C33c. Figure 9 schematically illustrates assembly of the vector C7fC20cC300C200. Figure 10 shows the sequence of vector cflSODpόOO. Modes of Carrying Out The Invention A. Definitions The terms "Hepatitis C Virus" and "HCV" refer to the viral species that is the major etiological agent of BB-NANBH, the prototype isolate of which is identified in PCT WO89/046699; EPO publication 318,216; USSN 7/355,008, filed 18 May 1989; and USSN 7/456,637, the disclosures of which are incorpor¬ ated herein by reference. "HCV as used herein includes the pathogenic strains capable of causing hepatitis C, and attenuated strains or defective interfering par- tides derived therefrom. The HCV genome is comprised of RNA. It is known that RNA-containing viruses have relatively high rates of spontaneous mutation, reportedly on the order of 10 -3 to 10 -4 per incorporated nucleotide (Fields & Knipe, "Fundamental Virology" (1986, Raven Press, N.Y.)). As heterogeneity and fluidity of genotype are inherent characteristics of RNA viruses, there will be mul- tiple strains/isolates, which may be virulent or avirulent, within the HCV species. Information on several different strains/isolates of HCV is disclosed herein, particularly strain or isolate CDC/HCVI (also called HCV1). Information from one strain or isolate, such as a partial genomic sequence, is sufficient to allow those skilled in the art using standard techniques to isolate new strains/ isolates and to identify whether such new strains/isolates are HCV. For example, several different strains/isolates are described below. These strains, which were obtained from a number of human sera (and from different geographical areas), were isolated utilizing the information from the genomic sequence of HCV1. The information provided herein suggests that HCV may be dis- tantly related to the flaviviridae. The Flavivinis family contains a large number of viruses which are small, enveloped pathogens of man. The morphology and com¬ position of Flavivinis particles are known, and are discussed in M.A. Brinton, in "The Viruses: The Togaviridae And Flaviviridae" (Series eds. Fraenkel-Conrat and Wagner, vol. eds. Schlesinger and Schlesinger, Plenum Press, 1986), pp. 327-374. Generally, with respect to morphology, Flaviviruses contain a central nucleocapsid surrounded by a lipid bilayer. Virions are spherical and have a diameter of about 40-50 nm. Their cores are about 25-30 nm in diameter. Along the outer surface of the virion envelope are projections measuring about 5-10 nm in length with ter¬ minal knobs about 2 nm in diameter. Typical examples of the family include Yellow Fever virus, West Nile virus, and Dengue Fever virus. They possess posi¬ tive-stranded RNA genomes (about 11,000 nucleotides) that are slightly larger than that of HCV and encode a polyprotein precursor of about 3500 amino acids. Individual viral proteins are cleaved from this precursor polypeptide. The genome of HCV appears to be single-stranded RNA containing about 10,000 nucleotides. The genome is positive-stranded, and possesses a con¬ tinuous translational open reading frame (ORF) that encodes a polyprotein of about 3,000 amino acids. In the ORF, the structural proteins appear to be encoded in approximately the first quarter of the N-terminal region, with the majority of the polyprotein attributed to non-structural proteins. When compared with all known viral sequences, small but significant co-linear homologies are observed with the non-structural proteins of the Flavivinis family, and with the pestiviruses (which are now also considered to be part of the Flavivinis family). A schematic alignment of possible regions of a flaviviral polyprotein (using Yellow Fever Virus as an example), and of a putative polyprotein encoded in the major ORF of the HCV genome, is shown in Figure 1. Possible domains of the HCV polyprotein are indicated in the figure. The Yellow Fever Virus poly¬ protein contains, from the amino terminus to the carboxy terminus, the nucleocap- sid protein (C), the matrix protein (M), the envelope protein (E), and the non- structural proteins 1, 2 (a+b), 3, 4 (a+b), and 5 (NS1, NS2, NS3, NS4, and NS5). Based upon the putative amino acids encoded in the nucleotide sequence of HCV1, a small domain at the extreme N-terminus of the HCV polyprotein appears similar both in size and high content of basic residues to the micleocapsid protein (C) found at the N-terminus of flaviviral polyproteins. The non-structural proteins 2,3,4, and 5 (NS2-5) of HCV and of yellow fever virus ( YFV) appear to have counterparts of similar size and hydropathicity, although the amino acid sequences diverge. However, the region of HCV which would correspond to the regions of YFV polyprotein which contains the M, E, and NS1 protein not only differs in sequence, but also appears to be quite different in size and hydropathic¬ ity. Thus, while certain domains of the HCV genome may be referred to herein as, for example, NS1, or NS2, it should be understood that these designations are for convenience of reference only; there may be considerable differences between the HCV family and flaviviruses that have yet to be appreciated. Due to the evolutionary relationship of the strains or isolates of HCV, putative HCV strains and isolates are identifiable by their homology at the polypeptide level. With respect to the isolates disclosed herein, new HCV strains or isolates are expected to be at least about 40% homologous, some more than about 70% homologous, and some even more than about 80% homologous: some may be more than about 90% homologous at the polypeptide level. The tech¬ niques for determining amino acid sequence homology are known in the art. For example, the amino acid sequence may be determined directly and compared to the sequences provided herein. Alternatively the nucleotide sequence of the gen¬ omic material of the putative HCV may be determined (usually via a cDNA inter¬ mediate), the amino acid sequence encoded therein can be determined, and the corresponding regions compared. The term "HCV protease" refers to an enzyme derived from HCV which exhibits proteolytic activity, specifically the polypeptide encoded in the NS3 domain of the HCV genome. At least one strain of HCV contains a protease believed to be substantially encoded by or within the following sequence: Arg Arg Gly Arg Glu He Leu Leu Gly Pro 10 Ala Asp Gly Met Val Ser Lys Gly Trp Arg 20 Leu Leu Ala Pro He Thr Ala Tyr Ala Gin 30 Gin Thr Arg Gly Leu Leu Gly Cys He He 40 Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin 50 Val Glu Gly Glu Val Gin He Val Ser Thr 60 Ala Ala Gin Thr Phe Leu Ala Thr Cys He 70 Asn Gly Val Cys Trp Thr Val Tyr Hjs Gly 80 Ala Gly Thr Arg Thr He Ala Ser Pro Lys 90 Gly Pro Val He Gin Met Tyr Thr Asn Val 100 Asp Gin A§p_ Leu Val Gly Trp Pro Ala Ser 110 Gin Gly Thr Arg Ser Leu Thr Pro Cys Thr 120 Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr 130 Arg His Ala Asp Val He Pro Val Arg Arg 140 Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser 150 Pro Arg Pro He Ser Tyr Leu Lys Gly Ser 160 Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly 170 His Ala Val Gly He Phe Arg Ala Ala Val 180 Cys Thr Arg Gly Val Ala Lys Ala Val Asp 190 Phe He Pro Val Glu Asn Leu Glu Thr Thr 200 Met Arg ••• 202 The above N and C termini are putative, the actual termini being defined by expression and processing in an appropriate host of a DNA construct encoding the entire NS3 domain. It is understood that this sequence may vary from strain to strain, as RNA viruses like HCV are known to exhibit a great deal of variation. Further, the actual N and C termini may vary, as the protease is cleaved from a precursor polyprotein: variations in the protease amino acid sequence can result in cleavage from the polyprotein at different points. Thus, the amino- and carboxy-termini may differ from strain to strain of HCV. The first amino acid shown above corresponds to residue 60 in Figure 1. However, the minimum sequence necessary for activity can be determined by routine methods. The sequence may be truncated at either end by treating an appropriate expres¬ sion vector with an exonuclease (after cleavage at the 5' or 3' end of the coding sequence) to remove any desired number of base pairs. The resulting coding polynucleotide is then expressed and the sequence determined. In this manner the activity of the resulting product may be correlated with the amino acid sequence: a limited series of such experiments (removing progressively greater numbers of base pairs) determines the minimum internal sequence necessary for protease activity. We have found that the sequence may be substantially trun- cated, particularly at the carboxy terminus, apparently with full retention of pro¬ tease activity. It is presently believed that a portion of the protein at the carboxy terminus may exhibit helicase activity. However, helicase activity is not required of the HCV proteases of the invention. The amino terminus may also be trun¬ cated to a degree without loss of protease activity. The amino acids underlined above are believed to be the residues necessary for catalytic activity, based on sequence homology to putative flavivinis serine proteases. Table 1 shows the alignment of the three serine protease cat¬ alytic residues for HCV protease and the protease obtained from Yellow Fever Virus, West Nile Fever virus, Murray Valley Fever virus, and Kunjin virus. Although the other four flavivinis protease sequences exhibit higher homology with each other than with HCV, a degree of homology is still observed with HCV. This homology, however, was not sufficient for indication by currently available alignment software. The indicated amino acids are numbered His-**-,, Asp 103 , and Ser 161 in the sequence listed above (His 139 , Asp j63 , and Ser 22 - in Figure 1). TABLE 1: Alignment of Active Residues by Sequence Alternatively, one can make catalytic residue assignments based on structural homology. Table 2 shows alignment of HCV with against the catalytic sites of several well-characterized serine proteases based on structural con¬ siderations: protease A from Streptomyces griseus , α-lytic protease, bovine trypsin, chymotrypsin, and elastase (M. James et al. Can J Biochem (1978) 56:396). Again, a degree of homology is observed. The HCV residues identified are numbered His 7β , Asp 125 , and Ser 161 in the sequence listed above. TABLE 2: Alignment of Active Residues by Structure The most direct manner to verify the residues essential to the active site is to replace each residue individually with a residue of equivalent stearic size. This is easily accomplished by site-specific mutagenesis and similar methods known in the art. If replacement of a particular residue with a residue of equiva¬ lent size results in loss of activity, the essential nature of the replaced residue is confirmed. "HCV protease analogs" refer to polypeptides which vary from the full length protease sequence by deletion, alteration and/or addition to the amino acid sequence of the native protease. HCV protease analogs include the trun¬ cated proteases described above, as well as HCV protease muteins and fusion proteins comprising HCV protease, truncated protease, or protease muteins. Alterations to form HCV protease muteins are preferably conservative amino acid substitutions, in which an amino acid is replaced with another naturally-occurring amino acid of similar character. For example, the following substitutions are con¬ sidered "conservative": Gly - Ala; Lys - Arg; Val *» He « Leu; Asn - Gin; and Asp - Glu; Phe - Trp «-> Tyr. Nonconservative changes are generally substitutions of one of the above amino acids with an amino acid from a different group (e.g., substituting Asn for Glu), or substituting Cys, Met, His, or Pro for any of the above amino acids. Substitutions involving common amino acids are conveniently performed by site specific muta- genesis of an expression vector encoding the desired protein, and subsequent expression of the altered form. One may also alter amino acids by synthetic or semi-synthetic methods. For example, one may convert cysteine or serine residues to selenocysteine by appropriate chemical treatment of the isolated protein. Alternatively, one may incorporate uncommon amino acids in standard in vitro protein synthetic methods. Typically, the total number of residues changed, deleted or added to the native sequence in the muteins will be no more than about 20, preferably no more than about 10, and most preferably no more than about 5. The term fusion protein generally refers to a polypeptide comprising an amino acid sequence drawn from two or more individual proteins. In the present invention, "fusion protein" is used to denote a polypeptide comprising the HCV protease, truncate, mutein or a functional portion thereof, fused to a non- HCV protein or polypeptide ("fusion partner"). Fusion proteins are most conven¬ iently produced by expression of a fused gene, which encodes a portion of one polypeptide at the 5' end and a portion of a different polypeptide at the 3' end, where the different portions are joined in one reading frame which may be expressed in a suitable host. It is presently preferred (although not required) to position the HCV protease or analog at the carboxy terminus of the fusion pro¬ tein, and to employ a functional enzyme fragment at the amino terminus. As the HCV protease is normally expressed within a large polyprotein, it is not expected to include cell transport signals (e.g., export or secretion signals). Suitable func¬ tional enzyme fragments are those polypeptides which exhibit a quantifiable activ¬ ity when expressed fused to the HCV protease. Exemplary enzymes include, with- out limitation, β-galactosidase (β-gal), β-lactamase, horseradish peroxidase (HRP), glucose oxidase (GO), human superoxide dismutase (hSOD), urease, and the like. These enzymes are convenient because the amount of fusion protein produced can be quantified by means of simple colorimetric assays. Alternatively, one may employ antigenic proteins or fragments, to permit simple detection and quantifica¬ tion of 'fusion proteins using antibodies specific for the fusion partner. The pres¬ ently preferred fusion partner is hSOD. B. General Method The practice of the present invention generally employs conven¬ tional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See for example J. Sambrook et al, "Molecular Cloning; A Laboratory Manual (1989); "DNA Cloning", Vol. I and II (D.N Glover ed. 1985); "Oligonucleotide Synthesis" (MJ. Gait ed, 1984); "Nucleic Acid Hybridization" (B.D. Hames & SJ. Higgins eds. 1984); 'Transcription And Translation" (B.D. Hames & SJ. Higgins eds. 1984); "Animal Cell Culture" (R.I. Freshney ed. 1986); "Immobilized Cells And Enzymes" (IRL Press, 1986); B. Perbal, "A Practical Guide To Molecular Cloning" (1984); the series, "Methods In Enzymology" (Academic Press, Inc.); "Gene Transfer Vectors For Mammalian Cells" (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Meth Enzymol (1987) 15_4 and 155 (Wu and Grossman, and Wu, eds., respectively); Mayer & Walker, eds. (1987), "Immunochemical Methods In Cell And Molecular Biology" (Academic Press, London); Scopes, "Protein Purification: Principles And Practice", 2nd Ed (Springer-Verlag, N.Y., 1987); and "Handbook Of Experimental Immunology", volumes I-IV (Weir and Blackwell, eds, 1986). Both prokaryotic and eukaryotic host cells are useful for expressing desired coding sequences when appropriate control sequences compatible with the designated host are used. Among prokaryotic hosts, E. coli is most frequently used. Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors com¬ patible with prokaryotic hosts are commonly derived from, for example, pBR322, a plasmid containing operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, which also contain sequences conferring antibiotic resist¬ ance markers. These plasmids are commercially available. The markers may be used to obtain successful transformants by selection. Commonly used prokaryotic control sequences include the β-lactamase (penicillinase) and lactose promoter systems (Chang et al. Nature (1977) 28:1056), the tryptophan (trp) promoter sys¬ tem (Goeddel et al, Nuc Acids Res (1980) 8:4057) and the lambda-derived P L promoter and N gene ribosome binding site (Shimatake et al. Nature (1981) 222:128) and the hybrid __\ promoter (De Boer et al. Proc Nat Acad Sci USA (1983) 222:128) derived from sequences of the irp_ and _lac UV5 promoters. The foregoing systems are particularly compatible with E. coli; if desired, other pro¬ karyotic hosts such as strains of Bacillus or Pseudomonas may be used, with cor¬ responding control sequences. Eukaryotic hosts include without limitation yeast and mammalian cells in culture systems. Yeast expression hosts include Saccharomyces, Klebsiella, Picia, and the like. Saccharomyces cerevisiae and Saccharomyces carlsbergensis and K lactis are the most commonly used yeast hosts, and are convenient fungal hosts. Yeast-compatible vectors carry markers which permit selection of successful trans¬ formants by conferring prototrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Yeast compatible vectors may employ the 2μ origin of replication (Broach et al, Meth Enzymol (1983) 101:307). the combination of CEN3 and ARS1 or other means for assuring replication, such as sequences which will result in incorporation of an appropriate fragment into the host cell genome. Control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes (Hess et al, J Adv Enzyme Reg (1968) At 149; Holland et al, Biochem (1978), 12:4900), including the promoter for 3-phos- phoglycerate kinase (R. Hitzeman et al, J Biol Chem (1980) 255:2073). Termin¬ ators may also be included, such as those derived from the enolase gene (Holland, J Biol Chem (1981) 256:1385). Particularly useful control systems are those which comprise the glyceraldehyde-3 phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and if secretion is desired, a leader sequence derived from yeast α- factor (see U.S. Pat. No. 4,870,008, incorporated herein by reference). A presently preferred expression system employs the ubiquitin leader as the fusion partner. Copending application USSN 7/390,599 filed 7 August 1989 disclosed vectors for high expression of yeast ubiquitin fusion pro¬ teins. Yeast ubiquitin provides a 76 amino acid polypeptide which is automat¬ ically cleaved from the fused protein upon expression. The ubiquitin amino acid sequence is as follows: Gin He Phe Val Lys Thr Leu Thr Gly Lys Thr He Thr Leu Glu Val Glu Ser Ser Asp Thr He Asp Asn Val Lys Ser Lys He Gin Asp Lys Glu Gly He Pro Pro Asp Gin Gin Arg Leu He Phe Ala Gly Lys Gin Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn He Gin Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly See also Ozkaynak et al, Nature (1984) .312:663-66. Polynucleotides encoding the ubiquitin polypeptide may be synthesized by standard methods, for example following the technique of Barr et al, J Biol Chem (1988) 26^:1671-78 using an Applied Biosystem 380A DNA synthesizer. Using appropriate linkers, the ubiquitin gene may be inserted into a suitable vector and ligated to a sequence encoding the HCV protease or a fragment thereof. In addition, the transcriptional regulatory region and the transcrip- tional initiation region which are operably linked may be such that they are not naturally associated in the wild-type organism. These systems are described in detail in EPO 120,551, published October 3, 1984; EPO 116,201, published August 22, 1984; and EPO 164,556, published December 18, 1985, all of which are commonly owned with the present invention, and are hereby incorporated herein by reference in full. Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, and a number of other cell lines. Suitable promoters for mammalian cells are also known in the art and include viral promoters such as that from Simian Virus 40 (SV40) (Fiers et al, Nature (1978) 222:113), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papil- loma virus (BPV). Mammalian cells may also require terminator sequences and poly-A addition sequences. Enhancer sequences which increase expression may also be included, and sequences which promote amplification of the gene may also be desirable (for example methotrexate resistance genes). These sequences are known in the art. Vectors suitable for replication in mammalian cells are known in the art, and may include viral replicons, or sequences which insure integration of the appropriate sequences encoding HCV epitopes into the host genome. For example, another vector used to express foreign DNA is Vaccinia virus. In this case the heterologous DNA is inserted into the Vaccinia genome. Techniques for the insertion of foreign DNA into the vaccinia virus genome are known in the art, and may utilize, for example, homologous recombination. The heterologous DNA is generally inserted into a gene which is non-essential to the virus, for example, the thymidine kinase gene (tk), which also provides a selectable marker. Plasmid vectors that greatly facilitate the construction of recombinant viruses have been described (see, for example, Mackett et al, J Virol (1984) 42:857; Chakrabarti et al, Mol Cell Biol (1985) 1:3403; Moss, in GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (Miller and Calos, eds., Cold Spring Harbor Laboratory, NY, 1987), p. 10). Expression of the HCV polypeptide then occurs in cells or ani¬ mals which are infected with the live recombinant vaccinia virus. In order to detect whether or not the HCV polypeptide is expressed from the vaccinia vector, BSC 1 cells may be infected with the recombinant vector and grown on microscope slides under conditions which allow expression. The cells may then be acetone-fixed, and immunofluorescence assays performed using serum which is known to contain anti-HCV antibodies to a polypeptide(s) encoded in the region of the HCV genome from which the HCV segment in the recombinant expression vector was derived. Other systems for expression of eukaryotic or viral genomes include insect cells and vectors suitable for use in these cells. These systems are known in the art, and include, for example, insect expression transfer vectors derived from the baculovirus Autographa califomica nuclear polyhedrosis virus (AcNPV), which is a helper-independent, viral expression vector. Expression vectors derived from this system usually use the strong viral polyhedrin gene promoter to drive expression of heterologous genes. Currently the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373 (see PCT W089/ 046699 and USSN 7/456,637). Many other vectors known to those of skill in the art have also been designed for improved expression. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and intro- duces a BamHI cloning site 32 bp downstream from the ATT; See Luckow and Summers, Virol (1989) 12:31). AcNPV transfer vectors for high level expression of nonfused foreign proteins are described in copending applications PCT WO89/046699 and USSN 7/456,637. A unique BamHI site is located following position -8 with respect to the translation initiation codon ATG of the polyhedrin gene. There are no cleavage sites for Smal, PstI, Bglll, Xbal or Sstl. Good expression of nonfused foreign proteins usually requires foreign genes that ideally have a short leader sequence containing suitable translation initiation signals pre- ceding an ATG start signal. The plasmid also contains the polyhedrin polyadenyl- ation signal and the ampicillin-resistaπce (amp) gene and origin of replication for selection and propagation in E. coli. Methods for the introduction of heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summer and Smith, Texas Agricultural Experiment Station Bulletin No. 1555; Smith et al, Mol Cell Biol (1983) 1:2156-2165; and Luckow and Summers, Virol (1989) 12:31). For example, the heterologous DNA can be inserted into a gene such as the polyhedrin gene by homologous recombination, or into a restriction enzyme site engineered into the desired baculovirus gene. The inserted sequences may be those which encode all or varying segments of the polyprotein, or other orfs which encode viral polypep¬ tides. For example, the insert could encode the following numbers of amino acid segments from the polyprotein: amino acids 1-1078; amino acids 332-662; amino acids 406-662; amino acids 156-328, and amino acids 199-328. The signals for post-translational modifications, such as signal pep- tide cleavage, proteolytic cleavage, and phosphorylation, appear to be recognized by insect cells. The signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells. Examples of the signal sequences from vertebrate cells which are effective in invertebrate cells are known in the art, for example, the human interleukin-2 sig- nal (IL2 C ) which signals for secretion from the cell, is recognized and properly removed in insect cells. Transformation may be by any known method for introducing poly- nucleotides into a host cell, including, for example packaging the polynucleotide in a virus and transducing a host cell with the virus, and by direct uptake of the poly¬ nucleotide. The transformation procedure used depends upon the host to be transformed. Bacterial transformation by direct uptake generally employs treat¬ ment with calcium or rubidium chloride (Cohen, Proc Nat Acad Sci USA (1972) .£2:2110; T. Maniatis et al, "Molecular Cloning; A Laboratory Manual" (Cold Spring Harbor Press, Cold Spring Harbor, NY, 1982). Yeast transformation by direct uptake may be carried out using the method of Hinnen et al, Proc Nat Acad Sci USA (1978) 25:1929. Mammalian transformations by direct uptake may be conducted using the calcium phosphate precipitation method of Graham and Van der Eb, Virol (1978) _5_2:546, or the various known modifications thereof. Other methods for introducing recombinant polynucleotides into cells, particularly into mammalian cells, include dextran-mediated transfection, calcium phosphate mediated transfection, polybrene mediated transfection, protoplast fusion, electro- poration, encapsulation of the polynucleotide(s) in liposomes, and direct micro- injection of the polynucleotides into nuclei. Vector construction employs techniques which are known in the art. Site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes. In general, about 1 μg of plasmid or DNA sequence is cleaved by 1 unit of enzyme in about 20 μL buffer solution by incuba¬ tion for 1-2 hr at 37°C. After incubation with the restriction enzyme, protein is removed by phenol/chloroform extraction and the DNA recovered by precipita¬ tion with ethanol. The cleaved fragments may be separated using polyacrylamide or agarose gel electrophoresis techniques, according to the general procedures described in Meth Enzvmol (1980) (65:499-560. Sticky-ended cleavage fragments may be blunt ended using E. coli DNA polymerase I (Klenow fragment) with the appropriate deoxynucleotide tri- phosphates (dNTPs) present in the mixture. Treatment with SI nuclease may also be used, resulting in the hydrolysis of any single stranded DNA portions. Ligations are carried out under standard buffer and temperature conditions using T4 DNA ligase and ATP; sticky end ligations require less ATP and less ligase than blunt end ligations. When vector fragments are used as part of a ligation mixture, the vector fragment is often treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase to remove the 5'-phos- phate, thus preventing religation of the vector. Alternatively, restriction enzyme digestion of unwanted fragments can be used to prevent ligation. Ligation mixtures are transformed into suitable cloning hosts, such as E. coli, and successful transformants selected using the markers incorporated (e.g., antibiotic resistance), and screened for the correct construction. Synthetic oligonucleotides may be prepared using an automated oligonucleotide synthesizer as described by Warner, DNA (1984) 1:401. If desired, the synthetic strands may be labeled with 32 P by treatment with polynuc¬ leotide kinase in the presence of 32 P-ATP under standard reaction conditions. DNA sequences, including those isolated from cDNA libraries, may be modified by known techniques, for example by site directed mutagenesis (see e.g., Zoller, Nuc Acids Res (1982) 10:6487). Briefly, the DNA to be modified is packaged into phage as a single stranded sequence, and converted to a double stranded DNA with DNA polymerase, using as a primer a synthetic oligonucleo¬ tide complementary to the portion of the DNA to be modified, where the desired modification is included in the primer sequence. The resulting double stranded DNA is transformed into a phage-supporting host bacterium. Cultures of the transformed bacteria which contain copies of each strand of the phage are plated in agar to obtain plaques. Theoretically, 50% of the new plaques contain phage having the mutated sequence, and the remaining 50% have the original sequence. Replicates of the plaques are hybridized to labeled synthetic probe at temper- atures and conditions which permit hybridization with the correct strand, but not with the unmodified sequence. The sequences which have been identified by hybridization are recovered and cloned. DNA libraries may be probed using the procedure of Grunstein and Hogness Proc Nat Acad Sci USA (1975) 23_:3961. Briefly, in this procedure the DNA to be probed is immobilized on nitrocellulose filters, denatured, and pre- hybridized with a buffer containing 0-50% formamide, 0.75 M NaCl, 75 mM Na citrate, 0.02% (wt/v) each of bovine serum albumin, polyvinylpyrrolidone, and Ficoll ® , 50 mM NaH 2 P0 4 (pH 6.5), 0.1% SDS, and 100 g/mL carrier denatured DNA. The percentage of formamide in the buffer, as well as the time and tem¬ perature conditions of the prehybridization and subsequent hybridization steps depend on the stringency required. Oligomeric probes which require lower strin¬ gency conditions are generally used with low percentages of formamide, lower temperatures, and longer hybridization times. Probes containing more than 30 or 40 nucleotides, such as those derived from cDNA or genomic sequences generally employ higher temperatures, e.g., about 40-42°C, and a high percentage formam¬ ide, e.g., 50%. Following prehybridization, S'-^P-labeled oligonucleotide probe is added to the buffer, and the filters are incubated in this mixture under hybridization conditions. After washing, the treated filters are subjected to autoradiography to show the location of the hybridized probe; DNA in corres¬ ponding locations on the original agar plates is used as the source of the desired DNA. For routine vector constructions, ligation mixtures are transformed into E. coli strain HB101 or other suitable hosts, and successful transformants sel- ected by antibiotic resistance or other markers. Plasmids from the transformants are then prepared according to the method of Clewell et al, Proc Nat Acad Sci USA (1969) _6_2: 1159, usually following chloramphenicol amplification (Clewell, 1 Bacteriol (1972) 110:667). The DNA is isolated and analyzed, usually by restric- tion enzyme analysis and/or sequencing. Sequencing may be performed by the dideoxy method of Sanger et al, Proc Nat Acad Sci USA (1977) 24:5463, as fur¬ ther described by Messing et al, Nuc Acids Res (1981) 2:309, or by the method of Maxam et al, Meth Enzymol (1980) i>5_:499. Problems with band compression, which are sometimes observed in GC-rich regions, were overcome by use of T- deazoguanosine according to Barr et al, Biotechniques (1986) 4:428. The enzyme-linked immunosorbent assay (ELISA) can be used to measure either antigen or antibody concentrations. This method depends upon conjugation of an enzyme to either an antigen or an antibody, and uses the bound enzyme activity as a quantitative label. To measure antibody, the known antigen is fixed to a solid phase (e.g., a microtiter dish, plastic cup, dipstick, plastic bead, or the like), incubated with test serum dilutions, washed, incubated with anti- immunoglobulin labeled with an enzyme, and washed again. Enzymes suitable for labeling are known in the art, and include, for example, horseradish peroxidase (HRP). Enzyme activity bound to the solid phase is usually measured by adding a specific substrate, and determining product formation or substrate utilization colorimetrically. The enzyme activity bound is a direct function of the amount of antibody bound. To measure antigen, a known specific antibody is fixed to the solid phase, the test material containing antigen is added, after an incubation the solid phase is washed, and a second enzyme-labeled antibody is added. After washing, substrate is added, and enzyme activity is measured colorimetrically, and related to antigen concentration. Proteases of the invention may be assayed for activity by cleaving a substrate which provides detectable cleavage products. As the HCV protease is believed to cleave itself from the genomic polyprotein, one can employ this auto- catalytic activity both to assay expression of the protein and determine activity. For example, if the protease is joined to its fusion partner so that the HCV pro- tease N-terminal cleavage signal (Arg-Arg) is included, the expression product will cleave itself into fusion partner and active HCV protease. One may then assay the products, for example by western blot, to verify that the proteins produced correspond in size to the separate fusion partner and protease proteins. It is pres- ently preferred to employ small peptide p-nitrophenyl esters or methylcoumarins, as cleavage may then be followed by spectrophotometric or fluorescent assays. Following the method described by E.D. Matayoshi et al, Science (1990) 2£Z:231- 35, one may attach a fluorescent label to one end of the substrate and a quench¬ ing molecule to the other end: cleavage is then determined by measuring the resulting increase in fluorescence. If a suitable enzyme or antigen has been employed as the fusion partner, the quantity of protein produced may easily be determined. Alternatively, one may exclude the HCV protease N-terminal cleav¬ age signal (preventing self-cleavage) and add a separate cleavage substrate, such as a fragment of the HCV NS3 domain including the native processing signal or a synthetic analog. In the absence of this protease activity, the HCV polyprotein should remain in its unprocessed form, and thus render the virus noninfectious. Thus, the protease is useful for assaying pharmaceutical agents for control of HCV, as compounds which inhibit the protease activity sufficiently will also inhibit viral infectivity. Such inhibitors may take the form of organic compounds, particularly compounds which mimic the cleavage site of HCV recognized by the protease. Three of the putative cleavage sites of the HCV polyprotein have the following amino acid sequences: Val-Ser-Ala-Arg-Arg // Gly-Arg-Glu-Ile-Leu-Leu-Gly Ala-Ile-Leu-Arg-Arg // His-Val-Gly-Pro- Val-Ser-Cys-Gln-Arg // Gly-Tyr- These sites are characterized by the presence of two basic amino acids immediately before the cleavage site, and are similar to the cleavage sites recognized by other flavivinis proteases. Thus, suitable protease inhibitors may be prepared which mimic the basic/basic/small neutral motif of the HCV cleavage sites, but substituting a nonlabile linkage for the peptide bond cleaved in the natural substrate. Suitable inhibitors include peptide trifluoromethyl ketones, peptide boronic acids, peptide α-ketoesters, peptide difluoroketo compounds, pep¬ tide aldehydes, peptide diketones, and the like. For example, the peptide alde¬ hyde N-acetyl-phenylalanyl-glycinaldehyde is a potent inhibitor of the protease papain. One may conveniently prepare and assay large mixtures of peptides using the methods disclosed in U.S. Patent application Serial No. 7/189,318, filed 2 May 1988 (published as PCT WO89/10931), incorporated herein by reference. This application teaches methods for generating mixtures of peptides up to hexapep- tides having all possible amino acid sequences, and further teaches assay methods for identifying those peptides capable of binding to proteases. Other protease inhibitors may be proteins, particularly antibodies and antibody derivatives. Recombinant expression systems may be used to gener¬ ate quantities of protease sufficient for production of monoclonal antibodies (MAbs) specific for the protease. Suitable antibodies for protease inhibition will bind to the protease in a manner reducing or eliminating the enzymatic activity, typically by obscuring the active site. Suitable MAbs may be used to generate derivatives, such as Fab fragments, chimeric antibodies, altered antibodies, unival- ent antibodies, and single domain antibodies, using methods known in the art. Protease inhibitors are screened using methods of the invention. In general, a substrate is employed which mimics the enzyme's natural substrate, but which provides a quantifiable signal when cleaved. The signal is preferably detectable by colorimetric or fluorometric means: however, other methods such as HPLC or silica gel chromatography, GC-MS, nuclear magnetic resonance, and the like may also be useful. After optimum substrate and enzyme concentrations are determined, a candidate protease inhibitor is added to the reaction mixture at a range of concentrations. The assay conditions ideally should resemble the con¬ ditions under which the protease is to be inhibited in vivo, i.e., under physiologic pH, temperature, ionic strength, etc. Suitable inhibitors will exhibit strong pro¬ tease inhibition at concentrations which do not raise toxic side effects in the sub¬ ject. Inhibitors which compete for binding to the protease active site may require concentrations equal to or greater than the substrate concentration, while inhib¬ itors capable of. binding irreversibly to the protease active site may be added in concentrations on the order of the enzyme concentration. In a presently preferred embodiment, an inactive protease mutein is employed rather than an active enzyme. It has been found that replacing a critical residue within the active site of a protease (e.g., replacing the active site Ser of a serine protease) does not significantly alter the structure of the enzyme, and thus preserves the binding specificity. The altered enzyme still recognizes and binds to its proper substrate, but fails to effect cleavage. Thus, in one method of the invention an inactivated HCV protease is immobilized, and a mixture of can¬ didate inhibitors added. Inhibitors that closely mimic the enzyme's preferred recognition sequence will compete more successfully for binding than other candi- date inhibitors. The poorly-binding candidates may then be separated, and the identity of the strongly-binding inhibitors determined. For example, HCV prot¬ ease may be prepared substituting Ala for Ser^ (Fig. 1), providing an enzyme capable of binding the HCV protease substrate, but incapable of cleaving it. The resulting protease mutein is then bound to a solid support, for example Sephadex ® beads, and packed into a column. A mixture of candidate protease inhibitors in solution is then passed through the column and fractions collected. The last frac¬ tions to elute will contain the strongest-binding compounds, and provide the pre¬ ferred protease inhibitor candidates. Protease inhibitors may be administered by a variety of methods, such as intravenously, orally, intramuscularly, iπtraperitoneally, bronchially, intra- nasally, and so forth. The preferred route of administration will depend upon the nature of the inhibitor. Inhibitors prepared as organic compounds may often be administered orally (which is generally preferred) if well absorbed. Protein-based inhibitors (such as most antibody derivatives) must generally be administered by parenteral routes. C. Examples The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art, and are not to be construed as limiting the invention in any way. Example 1 (Preparation of HCV cDNA) A genomic library of HCV cDNA was prepared as described in PCT WO89/046699 and USSN 7/456,637. This library, ATCC accession no. 40394, has been deposited as set forth below. Example 2 (Expression of the Polypeptide Encoded in Clone 5-1-1.) (A) The HCV polypeptide encoded within clone 5-1-1 (see Example 1) was expressed as a fusion polypeptide with human superoxide dis- mutase (SOD). This was accomplished by subcloning the clone 5-1-1 cDNA insert into the expression vector pSODCFl (K.S. Steimer et al, J Virol (1986) i8:9; EPO 138,111) as follows. The SOD/5-1-1 expression vector was transformed into E. coli D1210 cells. These cells, named Cfl/5-1-1 in E. coli, were deposited as set forth below and have an ATCC accession no. of 67967. First, DNA isolated from pSODCFl was treated with BamHI and EcoRI, and the following linker was ligated into the linear DNA created by the restriction enzymes: GAT CCT GGA ATT CTG ATA AGA CCT TAA GAC TAT TTT AA After cloning, the plasmid containing the insert was isolated. Plasmid containing the insert was restricted with EcoRI. The HCV cDNA insert in clone 5-1-1 was excised with EcoRI, and ligated into this EcoRI linearized plasmid DNA. The DNA mixture was used to transform E. coli strain D1210 (Sadler et al, Gene (1980) .8:279). Recombinants with the 5-1-1 cDNA in the correct orientation for expressing the ORF shown in Figure 1 were identified by restriction mapping and nucleotide sequencing. Recombinant bacteria from one clone were induced to express the SOD-HCVc ι ι polypeptide by growing the bacteria in the presence of IPTG. Three separate expression vectors, pcflAB, pcflCD, and pcflEF were created by ligating three new linkers, AB, CD, and EF to a BamHI-EcoRI fragment derived by digesting to completion the vector pSODCFl with EcoRI and BamHI, followed by treatment with alkaline phosphatase. The linkers were created from six oligomers, A, B, C, D, E, and F. Each oligomer was phosphoryl- ated by treatment with kinase in the presence of ATP prior to annealing to its complementary oligomer. The sequences of the synthetic linkers were the follow¬ ing: Name DNA Sequence (5' to 3 . A GATC CTG AAT TCC TGA TAA B GAC TTA AGG ACT ATT TTA A C GATC CGA ATT CTG TGA TAA D GCT TAA GAC ACT ATT TTA A E GATC CTG GAA TTC TGA TAA F GAC CTT AAG ACT ATT TTA A Each of the three linkers destroys the original EcoRI site, and creates a new EcoRI site within the linker, but within a different reading frame. Thus, the HCV cDNA EcoRI fragments isolated from the clones, when inserted into the expression vector, were in three different reading frames. The HCV cDNA fragments in the designated gtll clones were excised by digestion with EcoRI; each fragment was inserted into pcf 1AB, pcflCD, and pcflEF. These expression constructs were then transformed into D1210 E. coli cells, the transformants cloned, and polypeptides expressed as described in part B below. (B) Expression products of the indicated HCV cDNAs were tested for antigenicity by direct immunological screening of the colonies, using a modification of the method described in Helfmaπ et al, Proc Nat Acad Sci USA (1983), .8j):31. Briefly, the bacteria were plated onto nitrocellulose filters overlaid on ampicillin plates to give approximately 40 colonies per filter. Colonies were replica plated onto nitrocellulose filters, and the replicas were regrown overnight in the presence of 2 mM IPTG and ampicillin. The bacterial colonies were lysed by suspending the nitrocellulose filters for about 15 to 20 min in an atmosphere saturated with C C vapor. Each filter then was placed in an individual 100 mm Petri dish containing 10 mL of 50 mM Tris HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 3% (w/v) BSA, 40 g/mL lysozyme, and 0.1 g/mL DNase. The plates were agitated gently for at least 8 hours at room temperature. The filters were rinsed in TBST (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 0.005% Tween ® 20). After incubation, the cell residues were rinsed and incubated for one hour in TBS (TBST without Tween ® ) containing 10% sheep serum. The filters were then incubated with pretreated sera in TBS from individuals with NANBH, which included 3 chimpanzees; 8 patients with chronic NANBH whose sera were pos¬ itive with respect to antibodies to HCV C100-3 polypeptide (also called C100); 8 patients with chronic NANBH whose sera were negative for anti-ClOO antibodies; a convalescent patient whose serum was negative for anti-ClOO antibodies; and 6 patients with community-acquired NANBH, including one whose sera was strongly positive with respect to anti-ClOO antibodies, and one whose sera was marginally positive with respect to anti-ClOO antibodies. The sera, diluted in TBS, was pre¬ treated by preabsorption with hSOD for at least 30 minutes at 37°C. After incu¬ bation, the filters were washed twice for 30 min with TBST. The expressed pro- teins which bound antibodies in the sera were labeled by incubation for 2 hours with 125 I-labeled sheep anti-human antibody. After washing, the filters were washed twice for 30 min with TBST, dried, and autoradiographed. Example 3 (Cloning of Full-Length SOD-Protease Fusion Proteins) (A) pBR322-C200: The nucleotide sequences of the HCV cDNAs used below were determined essentially as described above, except that the cDNA excised from these phages were substituted for the cDNA isolated from clone 5-1-1. Clone C33c was isolated using a hybridization probe having the fol¬ lowing sequence: 5' ATC AGG ACC GGG GTG AGA ACA ATT ACC ACT 3' The sequence of the HCV cDNA in clone C33c is shown in Figure 8, which also shows the amino acids encoded therein. Clone 35 was isolated by screening with a synthetic polynucleotide having the sequence: 5' AAG CCA CCG TGT GCG CTA GGG CTC AAG CCC 3' Approximately 1 in 50,000 clones hybridized with the probe. The polynucleotide and deduced amino acid sequences for C35 are shown in Figure 7. Clone C31 is shown in Figure 6, which also shows the amino acids encoded therein. A C200 cassette was constructed by ligating together a 718 bp fragment obtained by digestion of clone C33c DNA with EcoRI and Hinfl, a 179 bp fragment obtained by digestion of clone C31 DNA with Hinfl and Bgll, and a 377 bp fragment obtained by digesting clone C35 DNA with Bgll and EcoRI. The construct of ligated fragments were inserted into the EcoRI site of pBR322, yield¬ ing the plasmid pBR322-C200. (B) C7f+C20c: Clone 7f was isolated using a probe having the sequence: 5'-AGC AGA CAA GGG GCC TCC TAG GGT GCA TAA T-3' The sequence of HCV cDNA in clone 7f and the amino acids encoded therein are shown in Figure 5. Clone C20c is isolated using a probe having the following sequence: 5'-TGC ATC AAT GGG GTG TGC TGG-3' The sequence of HCV cDNA in clone C20c, and the amino acids encoded therein are shown in Figure 2. Clones 7f and C20c were digested with EcoRI and SfaNI to form 400 bp and 260 bp fragments, respectively. The fragments were then cloned into the EcoRI site of pBR322 to form the vector C7f + C20c, and transformed into HB101 cells. (C) ____: Clone 8h was isolated using a probe based on the sequence of nuc¬ leotides in clone 33c. The nucleotide sequence of the probe was 5'-AGA GAC AAC CAT GAG GTC CCC GGT GTT C-3\ The sequence of the HCV cDNA in clone 8h, and the amino acids encoded therein, are shown in Figure 4. Clone C26d is isolated using a probe having the following sequence: 5'-CTG TTG TGC CCC GCG GCA GCC-3' The sequence and amino acid translation of clone C26d is shown in Figure 3. Clones C26d and C33c (see part A above) were transformed into the methylation minus E. coli strain GM48. Clone C26d was digested with EcoRII and Ddel to provide a 100 bp fragment. Clone C33c was digested with EcoRII and EcoRI to provide a 700 bp fragment. Clone C8h was digested with EcoRI and Ddel to provide a 208 bp fragment. These three fragments were then ligated into the EcoRI site of pBR322, and transformed into E. coli HB101, to provide the vector C300. (D) Preparation of Full Length Clones: A 600 bp fragment was obtained from C7f+C20c by digestion with EcoRI and Nael, and ligated to a 945 bp Nael/EcoRI fragment from C300, and the construct inserted into the EcoRI site of pGEM4Z (commercially available from Promega) to form the vector C7fC20cC300. C7fC20cC300 was digested with Ndel and EcoRI to provide a 892 bp fragment, which was ligated with a 1160 bp fragment obtained by digesting C200 with Ndel and EcoRI. The resulting construct was inserted into the EcoRI site of pBR322 to provide the vector C7fC20cC300C200. Construction of this vec¬ tor is illustrated schematically in Figure 9. Example 4 (Preparation of E. coli Expression Vectors) (A) cflSODpόOO: This vector contains a full-length HCV protease coding sequence fused to a functional hSOD leader. The vector C7fC20cC300C200 was cleaved with EcoRI to provide a 2000 bp fragment, which was then ligated into the EcoRI site of plasmid cflCD (Example 2A). The resulting vector encodes amino acids 1- 151 of hSOD, and amino acids 946-1630 of HCV (numbered from the beginning of the polyprotein, corresponding to amino acids 1-686 in Figure 1). The vector was labeled cflSODpόOO (sometimes referred to as P600), and was transformed into E. coli D1210 cells. These cells, ATCC accession no. 68275, were deposited as set forth below. (B) P190: A truncated SOD-protease fusion polynucleotide was prepared by excising a 600 bp EcoRI/Nael fragment from C7f + C20c, blunting the fragment with Klenow fragment, ligating the blunted fragment into the Klenow-blunted EcoRI site of cflEF (Example 2A). This polynucleotide encodes a fusion protein having amino acids 1-151 of hSOD, and amino acids 1-199 of HCV protease. (C) P2QQ: A longer truncated SOD-protease fusion polynucleotide was pre¬ pared by excising an 892 bp EcoRI/Ndel fragment from C7fC20cC300, blunting the fragment with Klenow fragment, ligating the blunted fragment into the Klenow-blunted EcoRI site of cflEF. This polynucleotide encodes a fusion pro¬ tein having amino acids 1-151 of hSOD, and amino acids 1-299 of HCV protease. (D) P500: A longer truncated SOD-protease fusion polynucleotide was pre¬ pared by excising a 1550 bp EcoRI/EcoRI fragment from C7fC20cC300, and ligat¬ ing the fragment into the EcoRI site of cflCD to form P500. This polynucleotide encodes a fusion protein having amino acids 1-151 of hSOD, and amino acids 946- 1457 of HCV protease (amino acids 1-513 in Figure 1). (E) FLAG/Protease Fusion This vector contains a full-length HCV protease coding sequence fused to the FLAG sequence, Hopp et al. (1988) Biotechnology 6: 1204-1210. PCR was used to produce a HCV protease gene with special restriction ends for cloning ease. Plasmid p500 was digested with EcoRI and Ndel to yield a 900 bp fragment. This fragment and two primers were used in a polymerase chain reaction to introduce a unique Bglll site at amino acid 1009 and a stop codon with a Sail site at amino acid 1262 of the HCV-1, as shown in Figure 17 of WO 90/11089, published 4 October 1990. The sequence of the primers is as follows: 5' CCC GAG CAA GAT CTC CCG GCC C 3' and 5' CCC GGC TGC ATA AGC AGT CGA CTT GGA 3' After 30 cycles of PCR, the reaction was digested with Bglll and Sail, and the 710 bp fragment was isolated. This fragment was annealed and ligated to the following duplex: MetAspTyrLysAspAspAspAspLysGlyArgGlu CATGGACTACAAAGACGATGACGATAAAGGCCGGGA CTGATGTTTCTGCTACTGCTATTTCCGGCCCTCTAG The duplex encodes the FLAG sequence, and initiator methionine, and a 5' Ncol restriction site. The resulting Ncol/Sall fragment was ligated into a derivative of pCFl. This construct is then transformed into E. coli D1210 cells and expression of the protease is induced by the addition of IPTG. The FLAG sequence was fused to the HCV protease to facilitate purification. A calcium dependent monoclonal antibody, which binds to the FLAG encoded peptide, is used to purify the fusion protein without harsh eluting conditions. Example 5 (E. coli Expression of SOD-Protease Fusion Proteins) (A) E. coli D1210 cells were transformed with cflSODp600 and grown in Luria broth containing 100 ,ug/mL ampicillin to an OD of 0.3-0.5. IPTG was then added to a concentration of 2 mM, and the cells cultured to a final OD of 0.9 to 1.3. The cells were then lysed, and the lysate analyzed by Western blot using anti- HCV sera, as described in USSN 7/456,637. The results indicated the occurrence of cleavage, as no full length product (theoretical Mr 93 kDa) was evident on the gel. Bands corresponding to the hSOD fusion partner and the separate HCV protease appeared at relative mol¬ ecular weights of about 34, 53, and 66 kDa. The 34 kDa band corresponds to the hSOD partner (about 20 kDa) with a portion of the NS3 domain, while the 53 and 66 kDa bands correspond to HCV protease with varying degrees of (possibly bacterial) processing. (B) E. coli D1210 cells were transformed with P500 and grown in Luria broth containing 100 /-Jg/mL ampicillin to an OD of 0.3-0.5. IPTG was then added to a concentration of 2 mM, and the cells cultured to a final OD of 0.8 to 1.0. The cells were then lysed, and the lysate analyzed as described above. The results again indicated the occurrence of cleavage, as no full length product (theoretical Mr 73 kDa) was evident on the gel. Bands corresponding to the hSOD fusion partner and the truncated HCV protease appeared at molecular weights of about 34 and 45 kDa, respectively. (C) E. coli D1210 cells were transformed with vectors P300 and P190 and grown as described above. The results from P300 expression indicated the occurrence of cleavage, as no full length product (theoretical Mr 51 kDa) was evident on the gel. A band corresponding to the hSOD fusion partner appeared at a relative molecular weight of about 34. The corresponding HCV protease band was not visible, as this region of the NS3 domain is not recognized by the sera employed to detect the products. However, appearance of the hSOD band at 34 kDa rather than 51 kDa indicates that cleavage occurred. The P190 expression product appeared only as the full (encoded) length product without cleavage, forming a band at about 40 kDa, which corresponds to the theoretical molecular weight for the uncleaved product. This may indicate that the minimum essential sequence for HCV protease extends to the region between amino acids 199 and 299. Example 6 (Purification of E. coli Expressed Protease) The HCV protease and fragments expressed in Example 5 may be purified as follows: The bacterial cells in which the polypeptide was expressed are subjected to osmotic shock and mechanical disruption, the insoluble fraction containing the protease is isolated and subjected to differential extraction with an alkaline-NaCI solution, and the polypeptide in the extract purified by chromatography on columns of S-Sepharose ® and Q-Sepharose ® . The crude extract resulting from osmotic shock and mechanical disruption is prepared by suspending 1 g of the packed cells in 10 mL of a solution con- taining 0.02 M Tris HCl, pH 7.5, 10 mM EDTA, 20% sucrose, and incubating for 10 minutes on ice. The cells are then pelleted by centrifugation at 4,000 x g for 15 min at 4°G. After the supernatant is removed, the cell pellets are resuspended in 10 mL of Buffer Al (0.01 M Tris HCl, pH 7.5, 1 mM EDTA, 14 mM β-mercap- toethanol - "βME"), and incubated on ice for 10 minutes. The cells are again pelleted at 4,000 x g for 15 minutes at 4°G. After removal of the clear super¬ natant (periplasmic fraction I), the cell pellets are resuspended in Buffer Al, incu¬ bated on ice for 10 minutes, and again centrifuged at 4,000 x g for 15 minutes at 4°G. The clear supernatant (periplasmic fraction II) is removed, and the cell pellet resuspended in 5 mL of Buffer T2 (0.02 M Tris HCl, pH 7.5, 14 mM βME, 1 mM EDTA, 1 mM PMSF). In order to disrupt the cells, the suspension (5 mL) and 7.5 mL of Dyno-mill lead-free acid washed glass beads (0.10-0.15 mm diam¬ eter) (available from Glen-Mills, Inc.) are placed in a Falcon tube and vortexed at top speed for two minutes, followed by cooling for at least 2 min on ice. The vortexing-cooling procedure is repeated another four times. After vortexing, the slurry is filtered through a sintered glass funnel using low suction, the glass beads washed twice with Buffer A2, and the filtrate and washes combined. The insoluble fraction of the crude extract is collected by centrifugation at 20,000 x g for 15 min at 4°C, washed twice with 10 mL Buffer A2, and resus¬ pended in 5 mL of MILLI-Q water. A fraction containing the HCV protease is isolated from the insoluble material by adding to the suspension NaOH (2 M) and NaCl (2 M) to yield a final concentation of 20 mM each, vortexing the mixture for 1 minute, centrifuging it 20,000 x g for 20 min at 4°C, and retaining the supernatant. The partially purified protease is then purified by SDS-PAGE. The pro¬ tease may be identified by western blot, and the band excised from the gel. The protease is then eluted from the band, and analyzed to confirm its amino acid sequence. N-terminal sequences may be analyzed using an automated amino acid sequencer, while C-terminal sequences may be analyzed by automated amino acid sequencing of a series of tryptic fragments. Example 7 (Preparation of Yeast Expression Vector) (A) P650 (SOD /Protease Fusion » This vector contains HCV sequence, which includes the wild-type full- length HCV protease coding sequence, fused at the 5' end to a SOD coding sequence. Two fragments, a 441 bp EcoRI/Bglll fragment from clone lib and a 1471 bp BglH/EcoRI fragment from expression vector P500, were used to reconstruct a wild-type, full-length HCV protease coding sequence. These two fragments were ligated together with an EcoRI digested pS356 vector to produce an expression cassette. The expression cassette encodes the ADH2/GAPDH hybrid yeast promoter, human SOD, the HCV protease, and a GAPDH transcription terminator. The resulting vector was digested with BamHI and a 4052 bp fragment was isolated. This fragment was ligated to the BamHI digested pAB24 vector to produce p650. p650 expresses a polyprotein containing, from its amino terminal end, amino acids 1-154 of hSOD, an oligopeptide -Asn-Leu-Gly- Ile-Arg- , and amino acids 819 to 1458 of HCV-1, as shown in Figure 17 of WO 90/11089, published 4 October 1990. Clone lib was isolated from the genomic library of HCV cDNA, ATCC accession no. 40394, as described above in Example 3A, using a hybridization probe having the following sequence: 5' CAC CTA TGT TTA TAA CCA TCT CAC TCC TCT 3'. This procedure is also described in EPO Pub. No. 318 216, Example IV.A.17. The vector pS3EF, which is a pBR322 derivative, contains the ADH2/GAPDH hybrid yeast promoter upstream of the human superoxide dimutase gene, an adaptor, and a downstream yeast effective transcription terminator. A similar expression vector containing these control elements and the superoxide dismutase gene is described in Cousens et al. (1987) Gene 61: 265, and in copending application EPO 196,056, published October 1, 1986. pS3EF, however, differs from that in Cousens et al. in that the heterologous proinsulin gene and the immunoglobulin hinge are deleted, and Gln 154 of SOD is followed by an adaptor sequence which contains an EcoRI site. The sequence of the adaptor is: 5' AAT TTG GGA ATT CCA TAA TTA ATT AAG 3' 3' AC CCT TAA GGT ATT AAT TAA TTC AGCT 5* The EcoRI site facilitates the insertion of heterologous sequences. Once inserted into pS3EF, a SOD fusion is expressed which contains an oligopeptide that links SOD to the heterologous sequences. pS3EF is exactly the same as pS356 except that pS356 contains a different adaptor. The sequence of the adaptor is shown below: 5' AAT TTG GGA ATT CCA TAA TGA G 3' 3' AC CCT TAA GGT ATT ACT CAG CT 5' pS356, ATCC accession no. 67683, is deposited as set forth below. Plasmid pAB24 is a yeast shuttle vector, which contains pBR322 sequences, the complete 2μ sequence for DNA replication in yeast (Broach (1981) in: Molecular Biology of the Yeast Saccharomyces. Vol. 1, p. 445, Cold spring Harbor Press.) and the yeast LEU 2d gene derived from plasmid pCl/1, described in EPO Pub. No. 116 201. Plasmid pAB24 was constructed by digesting YEp24 with EcoRI and re-ligating the vector to remove the partial 2 micron sequences. The resulting plasmid, YEp24deltaRI, was linearized with Clal and ligated with the complete 2 micron plasmid which had been linearized with Clal. The resulting plasmid, pCBou, was then digested with Xbal, and the 8605 bp vector fragment was gel isolated. This isolated Xbal fragment was ligated with a 4460 bp Xbal fragment containing the LEU 2d gene isolated from pCl/1; the orientation of LEU 2d gene is in the same direction as the URA3 gene. S. cerevisae, 2150-2-3 (pAB24-GAP-env2), accession no. 20827, is deposited " :h the American Type Culture Collection as set forth below. The plasmid pAiϊ24-GAP-env2 can be recovered from the yeast cells by known techniques. The GAP-env2 expression cassette can be removed by digesting pAB24-GAP-env2 with BamHI. pAB24 is recovered by religating the vector without the BamHI insert. Example 8 (Yeast Expression of SOD-Protease Fusion Protein) p650 was transformed in S. cerevisae strain JSC310, Mata, leu2, ura3-52, prbl-1122, pep4-3, prcl-407, cir°: DM15 (g418 resistance). The transformation is as described by Hinnen et al. (1978) Proc Natl Acad Sci USA 75: 1929. The transformed cells were selected on ura- plates with 8% glucose. The plates were incubated at 30°C for 4-5 days. The tranformants were further selected on leu- plates with 8% glucose putatively for high numbers of the p650 plasmid. Colonies from the leu- plates were inoculated into leu- medium with 3% glucose. These cultures were shaken at 30°C for 2 days and then diluted 1/20 into YEPD medium with 2% glucose and shaken for 2 more days at 30°C. S. cerevisae JSC310 contains DM15 DNA, described in EPO Pub. No. 340 986, published 8 November 1989. This DM15 DNA enhances ADH2 regulated expression of heterologous proteins. pDM15, accession no. 40453, is deposited with the American Type Culture Collection as set forth below. Example 9 (Yeast Ubiquitin Expression of Mature HCV Protease) Mature HCV protease is prepared by cleaving vector C7fC20cC300C200 with EcoRI to obtain a 2 Kb coding sequence, and inserting the sequence with the appropriate linkers into a ubiquitin expression vector, such as that described in WO 88/02406, published 7 April 1988, or USSN 7/390,599 filed 7 August 1989, incorporated herein by reference. Mature HCV protease is recovered upon expression of the vector in suitable hosts, particularly yeast. Specifically, the yeast expression protocol described in Example 8 is used to express a ubiquitin/HCV protease vector. Example 10 (Preparation of an In- Vitro Expression Vector) (A) pGEM ® -3Z/Yellow Fever Leader Vector Four synthetic DNA fragments were annealed and ligated** together to create a EcoRI/SacI Yellow Fever leader, which was ligated to a EcoRI/SacI digested pGEM ® -3Z vector from Promega ® . The sequence of the four fragments are listed below: YFK-1: 5'AATTCGTAAATCCTGTGTGCTAATTGAGGTGCATTG GTC TGCAAATCGAGTTGCTAG GCAATAAACACATT3' YFK-2: 5'TATTGCCTAGCAACTCGATTTGCAGACCAATGCACCTCAATT AGCACACAG GATTTACG3' YFK-3: 5'TGGATTAATTTTAATCGTTCGTTGAGCGATTAG CAGAGA ACTGACCAGAACATGTCTGAG CT3' YFK-4: 5' CAGACATGTTCTGGTCAG TTCTCTGCTAATCGCTCAACG AAC GATTAAAATTAATCCAAATGTGTT3'. For in-vitro translation of the HCV protease, the new pGEM ® - 3Z/Yellow Fever leader vector was digested with BamHI and blunted with Klenow. (B) PvuII Construct from p6000 A clone p6000 was constructed from sequences available from the genomic library of HCV cDNA, ATCC accession no. 40394. The HCV encoding DNA sequence of p6000 is identical to nucleotide -275 to nucleotide 6372 of Figure 17 of WO 90/11089, published 4 October 1990. p6000 was digested with PvuII, and from the digest, a 2,864 bp fragment was isolated. This 2,864 bp fragment was ligated to the prepared pGEM ® -3Z/Yellow Fever leader vector fragment, described above. Example 11 (In-Vitro Expression of HCV Protease) (A) Transcription The pGEM ® -3Z/Yellow Fever leader/PvuII vector was linearized with Xbal and transcribed using the materials and protocols from Promega's Riboprobe ® Gemini II Core system. (B) Translation The RNA produced by the above protocol was translated using Promega's rabbit reticulocyte lysate, minus methionine, canine pancreatic microsomal membranes, as well as, other necessary materials and instructions from Promega. Deposited Biological Materials: The following materials were deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Dr., Rockville, Maryland: E. coli HB101, pS356 29 Apr 1988 67683 plasmid DNA, pDM15 05 May 1988 40453 S. cerevisae, 2150-2-3 23 Dec 1986 20827 (pAB24-GAP-env2) The above materials have been deposited with the ATCC under the accession numbers indicated. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro¬ organisms for purposes of Patent Procedure. These deposits are provided as a convenience to those of skill in the art, and are not an admission that a deposit is required under 35 U.S.C. §112. The polynucleotide sequences contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the sequences described herein. A license may be required to make, use or sell the deposited materials, and no such license is granted hereby.

Claims: WHAT IS CLAIMED: 1. A composition comprising a purified proteolytic polypeptide derived from Hepatitis C virus. 2. The composition of claim 1, wherein said polypeptide has a par¬ tial internal sequence substantially as follows: —Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr««. 3. The composition of claim 1, wherein said polypeptide has a partial internal sequence substantially as follows: •••Leu Lys Gly Ser Ser Gly Gly Pro Leu*»». 4. The composition of claim 2, wherein said polypeptide has sub- stantially the partial internal sequence: Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Pro Gin Gly Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly He Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg. 5. The composition of claim 1, wherein said polypeptide has substantially the amino acid sequence shown in Figure 1. 6. A fusion protein, comprising: a suitable fusion partner, fused to a proteolytic polypeptide derived from Hepatitis C virus. 7. The fusion protein of claim 6, wherein said fusion partner comprises human superoxide dismutase. 8. The fusion protein of claim 6, wherein said proteolytic polypeptide has a partial internal sequence substantially as follows: •••Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr««. 9. The fusion protein of claim 6, wherein said proteolytic polypeptide has a partial internal sequence substantially as follows: •••Leu Lys Gly Ser Ser Gly Gly Pro Leu»»». 10. The fusion protein of claim 6, wherein said proteolytic polypeptide has as a partial internal sequence: Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Pro Gin Gly Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly He Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg. 11. The fusion protein of claim 6, wherein said fusion partner is ubiquiti 12. A composition comprising a polynucleotide which encodes only the HCV protease or an active HCV protease analog. 13. The composition of claim 12, wherein said polynucleotide encodes the HCV protease of Figure 1. 14. A composition comprising a polynucleotide which encodes a fusion protein comprising: HCV protease or HCV protease analog; and a fusion partner. 15. The composition of claim 14, wherein said fusion partner is selected from the group consisting of hSOD, yeast α-factor, IL-2S, ubiquitin, β- galactosidase, β-lactamase, horseradish peroxidase, glucose oxidase, and urease. 16. The composition of claim 14, wherein said HCV protease or HCV protease analog comprises a polypeptide having substantially the following sequence: Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Pro Gin Gly Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly He Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg. 17. The composition of claim 14, wherein said HCV protease or analog comprises a polypeptide having substantially the sequence: Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu Pro Val Val Phe Ser Gin Met Glu Thr Lys Leu He Thr Trp Gly Ala Asp Thr Ala Ala Cys Gly Asp He He Asn Gly Leu Pro Val Ser Ala Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Ser Gin Gly Thr Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly He Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gin Ser Phe Gin Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala. 18. The composition of claim 14, wherein said polypeptide has substantially the sequence: Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu Pro Val Val Phe Ser Gin Met Glu Thr Lys Leu He Thr Trp Gly Ala Asp Thr Ala Ala Cys Gly Asp He He Asn Gly Leu Pro Val Ser Ala Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Ser Gin Gly Thr Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg. 19. A method for assaying compounds for activity against hepatitis C virus, comprising: providing an active hepatitis C virus protease; contacting said protease with a compound capable of inhibiting serine protease activity; and measuring inhibition of the proteolytic activity of said hepatitis C virus protease. 20. An expression vector for producing HCV protease or HCV protease analogs in a host cell, which vector comprises: a polynucleotide encoding HCV protease or an HCV analog; transcriptional and translational regulatory sequences functional in said host cell operably linked to said HCV protease-encoding polynucleotide; and a selectable marker. 21. The vector of claim 20, which further comprises a sequence encoding a fusion partner, linked to said HCV protease-encoding polynucleotide to form a fusion protein upon expression. 22. The vector of claim 21, wherein said fusion partner is selected from the group consisting of hSOD, yeast α-factor, IL-2S, ubiquitin, β- galactosidase, β-lactamase, horseradish peroxidase, glucose oxidase, and urease. 23. The vector of claim 22, wherein said fusion partner is selected from the group consisting of ubiquitin, hSOD, and yeast α-factor. 24. The vector of claim 20, wherein said HCV protease-encoding polynucleotide encodes a polypeptide having the substantially the following sequence: Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Pro Gin Gly Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly He Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg. 25. The vector of claim 20, wherein said HCV protease-encoding polynucleotide encodes a polypeptide having the substantially the following sequence: Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu Pro Val Val Phe Ser Gin Met Glu Thr Lys Leu He Thr Trp Gly Ala Asp Thr Ala Ala Cys Gly Asp He He Asn Gly Leu Pro Val Ser Ala Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Ser Gin Gly Thr Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg. 26. The vector of claim 20, wherein said HCV protease-encoding polynucleotide encodes a polypeptide having the substantially the following sequence: Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu Pro Val Val Phe Ser Gin Met Glu Thr Lys Leu He Thr Trp Gly Ala Asp Thr Ala Ala Cys Gly Asp He He Asn Gly Leu Pro Val Ser Ala Arg Arg Gly Arg Glu He Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val Gin He Val Ser Thr Ala Ala Gin Thr Phe Leu Ala Thr Cys He He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Ser Gin Gly Thr Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly He Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gin Ser Phe Gin Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala.

Inventors: CHOO QUI-LIM, HOUGHTON MICHAEL, KUO GEORGE, CHOO, QUI-LIM, HOUGHTON, MICHAEL, KUO, GEORGE
Applicants: CHIRON CORP, CHIRON CORPORATION
Application year: 1991
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N9, C12N15, C12Q1, C12R1